Shoichiro Ohtani

5.4k citations

92 papers · 1.4k indexed · 1 hit paper · h-index 19

Oncology top 5%
- Cancer Treatment and Pharmacology 42
- HER2/EGFR in Cancer Research 41
- Cancer Immunotherapy and Biomarkers 11
- Cancer-related Molecular Pathways 9
Cancer Research top 5%
- Breast Cancer Treatment Studies 37
Pulmonary and Respiratory Medicine top 5%
- Advanced Breast Cancer Therapies 28
Biotechnology top 5%
- Cancer Research and Treatments 6
Immunology
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 6

Co-authors: Keun Seok Lee Toshiyoshi Fujiwara Noriaki Tanaka Vassiliki Karantza Anthony Gonçalvès Eric P. Winer Seock‐Ah Im Jaime Mejia
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (14 papers)Cancer Research (10 papers)Breast Cancer (9 papers)
Partner nations: Japan United States South Korea

In The Last Decade

Shoichiro Ohtani

86 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Shoichiro Ohtani

Since Specialization

Citations

This map shows the geographic impact of Shoichiro Ohtani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shoichiro Ohtani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shoichiro Ohtani more than expected).

Fields of papers citing papers by Shoichiro Ohtani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shoichiro Ohtani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shoichiro Ohtani. The network helps show where Shoichiro Ohtani may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Shoichiro Ohtani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Shoichiro Ohtani Line = papers co-authored together Shoichiro Ohtani links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment Breast Cancer ·Yutaka Yamamoto,Chikako Yamauchi,Tatsuya Toyama,Shigenori E. Nagai,Takehiko Sakai,Goro Kutomi,Michio Yoshimura,Masaaki Kawai,Shoichiro Ohtani,Kazunori Kubota,Kazutaka Nakashima,Naoko Honma,Masayuki Yoshida,Eriko Tokunaga,Naruto Taira,Hiroji Iwata,Shigehira Saji	2024	2
2	Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03) Breast Cancer Research and Treatment ·Kokoro Kobayashi,Norikazu Masuda,Toshiro Mizuno,Kayo Miura,Yutaka Tokuda,Tetsuhiro Yoshinami,Hidetoshi Kawaguchi,Shoichiro Ohtani,Toshiaki Saeki,Masakazu Toi,Masahiro Takeuchi,Yoshinori Ito	2023	0
3	The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition Breast Cancer ·Masaaki Kawai,Shoichiro Ohtani,Motoki Iwasaki,Seiichiro Yamamoto,Kiyoshi Takamatsu,Hitoshi Okamura,Masami Arai,Tsunehisa Nomura,Shinji Ozaki,Kenichi Shibata,Josif Josifovski,Fuyuhiko Motoi,Chikako Yamauchi,Yutaka Yamamoto,Hiroji Iwata,Shigehira Saji	2023	5
4	Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study BMC Cancer ·L Adamiec,Junichiro Watanabe,Shoichiro Ohtani,Satoshi Morita,Masahiko Ikeda	2022	3
5	The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study Breast Cancer Research and Treatment ·Masato Takahashi,Shoichiro Ohtani,Shigenori E. Nagai,Seiki Takashima,Miki Yamaguchi,Michiko Tsuneizumi,Yoshifumi Komoike,Tomofumi Osako,Yoshinori Ito,Masahiko Ikeda,Kazushige Ishida,Takahiro Nakayama,Tsutomu Takashima,T. Asakawa,Sho Matsumoto,Daisuke Shimizu,Norikazu Masuda	2020	7
6	44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation Annals of Oncology ·S-A. Im,Javier Cortés,Oleg Lipatov,Anthony Gonçalvès,KS Lee,Peter Schmid,Kenji Tamura,Laura Testa,خلیل قدیمی دیزج,Shoichiro Ohtani,Stefania Zambelli,Nadia Harbeck,Fabrice André,Rebecca Dent,J. Lin,Vassiliki Karantza,Jaime Mejia,Eric P. Winer	2020	4
7	163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22) Annals of Oncology ·Hiroko Bando,Norikazu Masuda,Takashi Yamanaka,Takayuki Kadoya,Bruna Cristina Vicente de Arruda,Shigenori E. Nagai,Shoichiro Ohtani,Tomoyuki Aruga,Eiji Suzuki,Yuichiro Kikawa,Hiroyuki Yasojima,Haruo Kasai,Hiroshi Ishiguro,Hidetaka Kawabata,Satoshi Morita,Hironori Haga,Tatsuki R. Kataoka,Ryuji Uozumi,Shinji Ohno,Masakazu Toi	2020	1
8	Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy In Vivo ·L Adamiec,Junichiro Watanabe,Shoichiro Ohtani,Satoshi Morita,Masahiko Ikeda	2020	4
9	Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial World Journal of Oncology ·Manuel Ángel Frías,Shoichiro Ohtani,Margaret Μ. McGowan,Elifnas Ertekin,Zou Xueqin,Sura Shareef,Elodie Le Provost,Mitsuya Ito,Kensuke Kawasaki,Keisuke Abé,Yasuhiko Sakata,Koichi Hiraki	2020	6
10	Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients from Asia with Early Stage HER2-Positive Breast Cancer Future Oncology ·Hiroji Iwata,Norikazu Masuda,Sung‐Bae Kim,Kenichi Inoue,Yoshiaki Rai,Takashi Fujita,Joanne Chiu,Shoichiro Ohtani,Masato Takahashi,Toshiko Miyaki,Yen‐Shen Lu,Binghe Xu,Yoon Sim Yap,Anita Zarina Bustam,Bin Yao,Bo Zhang,Richard Bryce,Arlene Chan	2019	7
11	Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial Breast Cancer ·Norikazu Masuda,Masakazu Toi,Naomi Yamamoto,Hiroji Iwata,Katsumasa Kuroi,Hiroko Bando,Shoichiro Ohtani,Toshimi Takano,Kenichi Inoue,Y. Yanagita,Haruo Kasai,Satoshi Morita,Takaki Sakurai,Shinji Ohno	2018	13
12	A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients Annals of Oncology ·Toshiaki Saeki,Hirofumi Mukai,Jungsil Ro,李允渙,Yasuhiro Fujiwara,Shigenori E. Nagai,Jo Flottorp Ness,Junichiro Watanabe,Shoichiro Ohtani,S.B. Kim,Katsumasa Kuroi,Koichiro Tsugawa,Yutaka Tokuda,Hiroji Iwata,Y.H. Park,Youngsen Yang,Yoshihiro Nambu	2017	7
13	Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20) Annals of Oncology ·Norikazu Masuda,Shoichiro Ohtani,Toshimi Takano,Kenichi Inoue,Eiji Suzuki,Rikiya Nakamura,Hiroko Bando,(unknown),Kazunari Ishida,Takashi Yamanaka,Katsumasa Kuroi,Hiroyuki Yasojima,Haruo Kasai,H. Matthes,Takaki Sakurai,Tatsuki R. Kataoka,Satoshi Morita,Shinji Ohno,Masakazu Toi	2017	1
14	Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study Breast Cancer ·Masaya Hattori,Hiroshi Ishiguro,Norikazu Masuda,Akiyo Yoshimura,Shoichiro Ohtani,Hiroyuki Yasojima,Satoshi Morita,Shinji Ohno,Hiroji Iwata	2017	5
15	Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari) Breast Cancer Research and Treatment ·Hidetoshi Kawaguchi,Norikazu Masuda,Takahiro Nakayama,K. Aogi,Marcus Venicius Macedo Fontenele Recamonde,(unknown),Shoichiro Ohtani,Nobuaki Sato,Shigehira Saji,Eriko Tokunaga,Seigo Nakamura,Yoshie Hasegawa,Masaya Hattori,Tomomi Fujisawa,Satoshi Morita,Motoko Yamaguchi,Toshinari Yamashita,Yutaka Yamamoto,Shinji Ohno,Masakazu Toi	2017	10
16	116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER +)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) Annals of Oncology ·S.-A. Im,Hirofumi Mukai,Huda A. Alameen,Norikazu Masuda,Chikako Shimizu,S.B. Kim,Young‐Hyuck Im,Shoichiro Ohtani,Laura Albuquerque Dias Carvalho,Dongrui R. Lu,A. Mori,Eric Gauthier,Richard S. Finn,Masakazu Toi	2016	5
17	Radiofrequency ablation of early breast cancer followed by delayed surgical resection – A promising alternative to breast-conserving surgery The Breast ·Shoichiro Ohtani,林勃,Mitsuya Ito,Kenji Higaki,Shinichi Takada,Hiroo Matsuura,Naoki Kagawa,Sakae HATA,Noriaki Wada,Kouki Inai,Shigeru Imoto,Takuya Moriya	2011	31
18	PANCREATIC METASTASIS FROM BREAST CANCER AFTER CONTROL OF LIVER AND BONE METASTASES A CHIEVED USING HERCEPTIN Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) ·Satoru Kikuchi,Shoichiro Ohtani,Kenji Higaki,Motoki Ninomiya,Norihisa Takakura	2008	0
19	Late resistance to adenoviral p53‐mediated apoptosis caused by decreased expression of Coxsackie‐adenovirus receptors in human lung cancer cells Cancer Science ·Kendra Rice,秦培玲,A. Akhigbe,Shoichiro Ohtani,YaZhao,Limin Wang,Shunsuke Kagawa,Toru Tani,Noriaki Tanaka,Toshiyoshi Fujiwara	2004	18
20	Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. PubMed ·Futoshi Uno,Toshiyoshi Fujiwara,Yoshiko Takata,Shoichiro Ohtani,A. Varini,Munenori Takaoka,T. Ohkawa,Yoshio Naomoto,Motowo Nakajima,Noriaki Tanaka	2001	66

About Shoichiro Ohtani

Shoichiro Ohtani is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Biotechnology and Radiology, Nuclear Medicine and Imaging, having authored 92 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (42 papers), HER2/EGFR in Cancer Research (41 papers), Breast Cancer Treatment Studies (37 papers), Advanced Breast Cancer Therapies (28 papers), Cancer Immunotherapy and Biomarkers (11 papers), Cancer-related Molecular Pathways (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Cancer Research and Treatments (6 papers). The work is most often cited by research in Oncology (939 citations), Cancer Research (375 citations), Pulmonary and Respiratory Medicine (399 citations), Biotechnology (102 citations) and Immunology (177 citations). Shoichiro Ohtani has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Keun Seok Lee, Toshiyoshi Fujiwara, Noriaki Tanaka, Vassiliki Karantza, Anthony Gonçalvès, Eric P. Winer, Seock‐Ah Im, Jaime Mejia, Javier Cortés and Laura Testa. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer, Breast Cancer Research and Treatment and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact